1 alpha(OH)D3 (ETALPHA) treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders.

Abstract

10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.

• Authors: S B Wieslander, B T Mortensen, L Binderup, N I Nissen
• Journal: European journal of haematology (Eur J Haematol) Vol. 39 Issue 1 Pg. 35-8 (Jul 1987) ISSN: 0902-4441 [Print] England
• PMID: 3477470 (Publication Type: Journal Article)

Chemical References

• Hydroxycholecalciferols
• Receptors, Drug
• alfacalcidol

Topics

• Humans
• Hydroxycholecalciferols (metabolism, therapeutic use)
• Leukemia, Lymphoid (blood, drug therapy, pathology)
• Leukemia, Myeloid (blood, drug therapy, pathology)
• Lymphocytes (ultrastructure)
• Myeloproliferative Disorders (blood, drug therapy, metabolism)
• Receptors, Drug (metabolism)